Phillip Scheinberg.

Results Features of the Patients A complete of 120 consecutive patients, 2 to 77 years of age, were randomly assigned to equine ATG or rabbit ATG . Features of the individuals are shown in Table 1Table 1Features of the Patients.; there have been no significant differences in demographic or clinical characteristics between your combined groups. The median follow-up was 839 days for all individuals and 891 days for surviving sufferers. Hematologic Response and Relapse The hematologic response rate at six months was 68 percent with horse ATG and 37 percent with rabbit ATG . The response rates at 3 and 6 months with horse ATG plus cyclosporine seen in this research were in accord with our experience with this regimen at our institution.6,10-12 The majority of patients had a reply within three months, and only four patients in the horse-ATG group and two in the rabbit-ATG group had a reply between 3 and six months.).Mountain Standard Time . Patients on Chronic Plasma Therapy Abstract #157, Protection and Efficacy of Eculizumab in aHUS Sufferers on Chronic Plasma Therapy: Interim Evaluation of a Phase 2 Trial, summarized interim outcomes from a report of 20 adolescent and adult sufferers with aHUS who were receiving plasma therapy chronically ahead of entering the study. The principal endpoint of the study is TMA Event-Free Status, as defined by steady platelet counts, absence of plasma therapy and no fresh dialysis.